133 related articles for article (PubMed ID: 4039984)
1. Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma.
Brindley CJ; Antoniw P; Newlands ES; Bagshawe KD
Cancer Chemother Pharmacol; 1985; 15(1):66-71. PubMed ID: 4039984
[TBL] [Abstract][Full Text] [Related]
2. VP-16 in combinations for first-line treatment of malignant germ-cell tumors and gestational choriocarcinoma.
Newlands ES
Semin Oncol; 1985 Mar; 12(1 Suppl 2):37-41. PubMed ID: 2579442
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma.
Newell DR; Eeles RA; Gumbrell LA; Boxall FE; Horwich A; Calvert AH
Cancer Chemother Pharmacol; 1989; 23(6):367-72. PubMed ID: 2469544
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of etoposide in gestochoriocarcinoma.
D'Incalci M; Sessa C; Rossi C; Roviaro G; Mangioni C
Cancer Treat Rep; 1985 Jan; 69(1):69-72. PubMed ID: 2981622
[TBL] [Abstract][Full Text] [Related]
5. The role of VP16-213 (etoposide; NSC-141540) in gestational choriocarcinoma.
Newlands ES; Bagshawe KD
Cancer Chemother Pharmacol; 1982; 7(2-3):211-4. PubMed ID: 7083462
[TBL] [Abstract][Full Text] [Related]
6. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
[TBL] [Abstract][Full Text] [Related]
8. Epipodophylin derivative (VP 16-23) in malignant teratomas and choriocarcinomas.
Newlands ES; Bagshawe KD
Lancet; 1977 Jul; 2(8028):87. PubMed ID: 69168
[No Abstract] [Full Text] [Related]
9. [A phase I study of VP-16-213 (VP, etoposide) by single and 5-day intravenous administration].
Wakui A; Yokoyama M; Takahashi H; Yoshida Y; Sakata Y; Sato S; Kano A; Kawamoto K; Hashimoto S; Konno K
Gan To Kagaku Ryoho; 1986 Feb; 13(2):319-29. PubMed ID: 3947109
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.
Hande KR; Wedlund PJ; Noone RM; Wilkinson GR; Greco FA; Wolff SN
Cancer Res; 1984 Jan; 44(1):379-82. PubMed ID: 6690051
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.
Stewart DJ; Nundy D; Maroun JA; Tetreault L; Prior J
Cancer Treat Rep; 1985 Mar; 69(3):269-73. PubMed ID: 3884152
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of high-dose etoposide after short-term infusion.
Köhl P; Köppler H; Schmidt L; Fritsch HW; Holz J; Pflüger KH; Jungclas H
Cancer Chemother Pharmacol; 1992; 29(4):316-20. PubMed ID: 1537079
[TBL] [Abstract][Full Text] [Related]
13. When is autologous bone marrow transplantation safe after high-dose treatment with etoposide?
Littlewood TJ; Spragg BP; Bentley DP
Clin Lab Haematol; 1985; 7(3):213-8. PubMed ID: 3907938
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of high-dose etoposide phosphate in man.
Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
[TBL] [Abstract][Full Text] [Related]
15. Primary oral etoposide therapy in gestational trophoblastic disease. An update.
Wong LC; Choo YC; Ma HK
Cancer; 1986 Jul; 58(1):14-7. PubMed ID: 3011237
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration.
Busse D; Würthwein G; Hinske C; Hempel G; Fromm MF; Eichelbaum M; Kroemer HK; Busch FW
Naunyn Schmiedebergs Arch Pharmacol; 2002 Sep; 366(3):218-25. PubMed ID: 12172704
[TBL] [Abstract][Full Text] [Related]
17. [VM-26 and VP-16 salvage therapy for refractory germinal testicular cancers].
Miki T; Tomooka Y; Yoshimura K; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
Nihon Hinyokika Gakkai Zasshi; 1989 Nov; 80(11):1609-16. PubMed ID: 2593435
[TBL] [Abstract][Full Text] [Related]
18. Variable bioavailability following repeated oral doses of etoposide.
Harvey VJ; Slevin ML; Joel SP; Smythe MM; Johnston A; Wrigley PF
Eur J Cancer Clin Oncol; 1985 Nov; 21(11):1315-9. PubMed ID: 3000790
[TBL] [Abstract][Full Text] [Related]
19. Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.
Stewart DJ; Richard MT; Hugenholtz H; Dennery JM; Belanger R; Gerin-Lajoie J; Montpetit V; Nundy D; Prior J; Hopkins HS
J Neurooncol; 1984; 2(2):133-9. PubMed ID: 6481426
[TBL] [Abstract][Full Text] [Related]
20. [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].
Schmoll HJ; Niederle N; Achterrath W
Klin Wochenschr; 1981 Nov; 59(21):1177-88. PubMed ID: 7031350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]